JosephBlaiseGuarnacciaMD

PubMed

• 1 citations
  Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis
  Joseph B. Guarnaccia, Ann Cabot, Lore Garten, Salvatore Napoli, Mayer J. Hasbani> ;Multiple Sclerosis and Related Disorders. 2021 Oct 28
• 27 citations
  Food craving, cortisol and ghrelin responses in modeling highly palatable snack intake in the laboratory.
  Rajita Sinha, Peihua Gu, Rachel Hart, Joseph Guarnaccia> ;Physiology & Behavior. 2019 Sep 1
• 42 citations
  Craving, cortisol and behavioral alcohol motivation responses to stress and alcohol cue contexts and discrete cues in binge and non-binge drinkers.
  Sara K. Blaine, Nisheet Nautiyal, Rachel Hart, Joseph Guarnaccia, Rajita Sinha> ;Addiction Biology. 2019 Sep 1
• Corrigendum to "Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo" [Yjaut 96C (2019) 40-49].
  Margarita Dominguez-Villar, Khadir Raddassi, Ann Caroline Danielsen, Joseph Guarnaccia, David A. Hafler> ;Journal of Autoimmunity. 2019 May 18
• 37 citations
  Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.
  Margarita Dominguez-Villar, Khadir Raddassi, Ann Caroline Danielsen, Joseph Guarnaccia, David A. Hafler> ;Journal of Autoimmunity. 2019 Jan 1
• 49 citations
  Sex differences in decreased limbic and cortical grey matter volume in cocaine dependence: a voxel-based morphometric study.
  Kenneth Rando, Keri Tuit, Jonas Hannestad, Joseph Guarnaccia, Rajita Sinha> ;Addiction Biology. 2013 Jan 1
• 229 citations
  Cumulative Adversity and Smaller Gray Matter Volume in Medial Prefrontal, Anterior Cingulate, and Insula Regions
  Emily B. Ansell, Kenneth Rando, Keri Tuit, Joseph Guarnaccia, Rajita Sinha> ;Biological Psychiatry. 2012 Jul 1
• 140 citations
  Association of Frontal and Posterior Cortical Gray Matter Volume With Time to Alcohol Relapse: A Prospective Study
  Kenneth Rando, Kwangik Hong, Zubin Bhagwagar, Chiang-Shan R. Li, Keri Bergquist, Joseph Guarnaccia, Rajita Sinha> ;The American Journal of Psychiatry. 2011 Feb 1
• 213 citations
  Factors that influence adherence with disease-modifying therapy in MS.
  Katherine Treadaway, Gary Cutter, Amber Salter, Sharon G. Lynch, James Simsarian, John R. Corboy, Douglas Jeffery, Bruce A. Cohen, Ken Mankowski, Joseph Guarnaccia, La...> ;Journal of Neurology. 2009 Apr 27
• Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease.
  Murinson, B.B., Guarnaccia, J.B.> ;Neurology. 2008-12-09
• 15 citations
  Quality of life for veterans with multiple sclerosis on disease-modifying agents: Relationship to disability.
  Joseph B. Guarnaccia, Mihaela Aslan, Theresa Z. O'Connor, MaryAnn Hope, Lewis E. Kazis, C. Michael Kashner, John Booss> ;Journal of Rehabilitation Research and Development. 2006 Jan 1
• 11 citations
  Predictors of short-term disease activity following a first clinical demyelinating event: Analysis of the CHAMPS placebo group
  Paul O'Connor, P. Fleming, Trevor A. Gray, Lawrence Jacobs, C. Miller, Frederick Munschauer, R. P. Kinkel, D. Bolibrush, Jeffrey A. Cohen, Mark S. Freedman, U. Webb, H...> ;Multiple Sclerosis. 2002 Jan 1
• 398 citations
  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo- cont...
  Ludwig Kappos, Giancarlo Comi, Hillel Panitch, Joel Oger, Jack P. Antel, Paul J. Conlon, Lawrence Steinman, Alexander Rae-Grant, John Castaldo, Nancy Eckert, Joseph Gu...> ;Nature Medicine. 2000 Oct 1
• 13 citations
  Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis
  Stuart D. Cook, Corinne Devereux, Raymond Troiano, Leo J. Wolansky, Joseph Guarnaccia, B. Haffty, S. Bansil, Jonathan Goldstein, Amiram Sheffet, George Zito, A. Jotkow...> ;Journal of the Neurological Sciences. 1997 Nov 25
• 16 citations
  Painless aortic dissection presenting as a progressive myelopathy
  Stephen F. Holloway, Pierre B. Fayad, Robert G. Kalb, Joseph Guarnaccia, Stephen G. Waxman> ;Journal of the Neurological Sciences. 1993 Dec 15
• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
  Johnson, K. P., Brooks, B. R., Ford, C. C., Goodman, A., Guarnaccia, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Pruitt, A., Rose, J. W., Kachuck, N., Wolinsky, J. S.> ;Mult Scler. 2000 Aug
• IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
  Kinkel, R. P., Kollman, C., O'Connor, P., Murray, T. J., Simon, J., Arnold, D., Bakshi, R., Weinstock-Gutman, B., Brod, S., Cooper, J., Duquette, P., Eggenberger, E., ...> ;Neurology. 2006 Mar 14
• Join now to see all